ABOUT US
We are a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Our lead product candidate is Nana-val, an all-oral combination therapy of our proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. We are also pursuing the application of our “Kick and Kill” approach in other virus-related cancers.
At Viracta, we recognize and celebrate one another’s accomplishments and empower each other to make a difference in the lives of patients with cancer.
>250K
new cases of EBV-associated cancers each year
>90%
world’s population asymptomatically infected with EBV
